Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile of human leukemic cell line with cMyc mutations

ABSTRACT: RNA-sequencing revealed that c-Myc-related gene signatures were negatively enriched in MV4;11(K148R) cells as compared to parental MV4;11, suggesting that lack of acetylation at K148 results in diminished c-Myc activity. In contrast, MV4;11(K148Q) cells exhibit a positive enrichment of c-Myc-regulated gene signatures as compared to MV4;11(K148R) cells, confirming that loss of acetylation of c-Myc at K148 results in diminished transcriptional activity in AML cells

ORGANISM(S): Homo sapiens

PROVIDER: GSE185295 | GEO | 2023/10/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profile of human leukemic cell line treated with TLR1/2 agonist.

Project description:Treatment of MV4;11 cells with CU-T12-9 increased ubiquitination of c-Myc compared to control and correspondingly resulted in reduced K148 acetylation. Chromatin immunoprecipitation coupled to high-throughput sequencing (Chip-Seq) revealed a significant loss of c-Myc occupancy in the genome following TLR1/2 activation with CU-T12-9. As expected, diminished c-Myc binding resulted in gene downregulation of well-establish c-Myc targets. These findings suggest that TLR-mediated K63-linked ubiquitination of c-Myc at K148 inhibits activation of c-Myc by interfering with its acetylation at the same residue.

2023-10-01 | GSE185299 | GEO

ChIP-Seq for cofactors in cancer

Project description:Critical drivers of cancer progression are likely controlled through the actions of transcription factors and cofactors that bind to the genome and form enhancers that stimulate gene expression. We present ChIP-seq analysis of key transcriptional regulators, cofactors and histone modifications that indicate transcriptional activity across a range of different cancer cells. ChIP-seq was performed against the cofactors Med1, Brd4 and CDK7 in MM1.S multiple myeloma cells; Brd4 in Sk-MEL-5 melanoma cells; and H3K9/K14 acetylation in MV4;11 leukemia cells,

2013-04-13 | E-GEOD-45984 | biostudies-arrayexpress

Gene expression analysis of cMyc-deficient CD8 T cells retrovirally overexpressing cMyc or AP4

Project description:To determine functional overlap between cMyc and AP4 in CD8+ T cell priming, we retrovirally expressed cMyc or AP4 in cMyc-deficient CD8+ T cells and examined gene expression after activation. Naive CD8+ T cells from Myc conditional knockout mice with a tamoxifen inducible Cre transgene were retrovirally transduced with Myc or AP4 followed by a treatment with 4-hydroxytamoxifen in the presence of IL-7 for 2 days. RNA was harvested 48 hours after restimulation of transduced cells with anti-CD3 antibody and gene expression was compared by microarray. CD8+ T cells from littermate wildtype mice that were transduced with an empty retrovirus were used as control.

2014-07-13 | E-GEOD-58079 | biostudies-arrayexpress

Effects of FTY720 on phospho-proteome of leukemic cells

Project description:: FTY720 (Fingolimod) is an immunosuppressive drug approved by FDA for Multiple Sclerosis (MS), that has gained attention as anti-cancer drug, thanks to its ability to disrupt the binding between the onco-protein SET and the tumor- suppressor phosphatase PP2A. We investigated FTY720 induced phospho-proteomic changes on acute myeloid leukemia cell lines carrying KMT2A-transocations. The phospho-proteomic data indicated that FTY720 treatment resulted in the down-regulation of phospho-sites associated to protein serine/threonine kinase activity, chromatin organisation and transcription. The findings support the hypothesis of a feedback loop between SET, PP2A and MYC, whereby FTY720 re-activates PP2A with an overall inhibitory effect on MYC, resulting in cell cycle arrest and apoptosis.

2024-01-26 | PXD038288 | Pride

TRAF6 is a tumor suppressor in AML by directly targeting MYC oncogenic activity [RNA-Seq]

Project description:Clonal hematopoiesis of indeterminant potential (CHIP) is an aging-associated condition characterized by the clonal outgrowth of self-renewing cells that acquire specific mutations. One of the most frequent mutations in CHIP targets the methylcytosine dioxygenase TET2, also observed in number of myeloid neoplasms 1,2. Although individuals with CHIP are healthy, they are at an increased risk of developing hematopoietic malignancies. These findings indicate that additional alterations are needed for the transition from a pre-leukemic (CHIP) stage to frank leukemia, although the identity of such molecular events remains poorly characterized. To identify signaling states that cooperate with CHIP mutant cells we used an in vivo RNAi screening approach. One of the most prominent genes identified was the ubiquitin ligase TRAF6. We demonstrate that TRAF6 is repressed in a subset of acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) patients. Loss of TRAF6 in pre-leukemic HSPC results in overt AML/MPN and is associated with induction of MYC-dependent leukemic stem cell signatures. TRAF6 represses MYC activity at enhancers due to the ubiquitination of MYC on Lysine (K)148. Ubiquitination of MYC on K148, does not affect protein stability but rather antagonizes acetylation of MYC on the same lysine and suppresses MYC oncogenic activity by preventing its DNA binding. Our results identify a novel tumor suppressor function for TRAF6 and demonstrate a novel mode of regulation of MYC oncogenic activity

2022-01-01 | GSE189172 | GEO

cMyc and Max ChIP-seq analysis in small cell lung carcinoma cells

Project description:cMyc and Max ChIP-seq analysis in a high MYC expressing small cell lung carcinoma cell line (H2171) and a low MYC expressing small cell lung carcinoma cell line (H128). H2171 cells (expressing high levels of cMyc protein) and H128 cells (expressing low levels of cMyc protein) were used to analyze how cMyc overexpression influences its genome-wide occupancy.

2012-09-25 | E-GEOD-41105 | biostudies-arrayexpress

Gene expression analysis during reprogramming with sequential infecion of Oct4/Klf4/cMyc/Sox2

Project description:To further understand the mechanism of reprogramming, the mouse embryonic fibroblast cells were infected with Oct4, Klf4, c-Myc and Sox2 with special sequence. 1) Oct4 and Klf4 containing retrovirus was delivered on day 0. 2) Oct4, Klf4 and c-Myc were delivered on Day 1.5. 3) c-Myc and Sox-2 were deivered on Day 3. 4) Sox2 were delivered on Day 4.5. 5) Vitamin C containging medium were used from Day 6. The gene expression of Day 0 (MEF), Day 1.5, Day 3, Day 4.5 and Day 6 were analyzed with micro array to indentify the possible underlying mechanism. Especially the factors related to MET/EMT, cell cycle and epigenetic were focused. MEF cells were subjected for reprogramming with special protoocl: 1) Oct4 and Klf4 containing retrovirus were delivered on day 0. 2) Oct4, Klf4 and c-Myc were delivered on Day 1.5. 3) c-Myc and Sox-2 were deivered on Day 3. 4) Sox2 were delivered on Day 4.5. 5) Vitamin C containging medium were used from Day 6. RNA on Day 0 (MEF), Day 1.5, Day 3, Day 4.5 and Day 6 were collected for analysis.

2012-07-11 | E-GEOD-39260 | biostudies-arrayexpress

RNA sequencing of 16D LTenza cells transduced with cMyc, shRb1, shTp53, shRb1_shTp53

Project description:The goal of this study was to determine how genetic alterations to AR inhibition-maintained prostate cancer cells alters transcriptional programs. We explored how MYC overexpression alters the transcriptional program of 16D cells maintained in enzalutamide for at least 2 months (LTenza) by transducing LTenza 16D cells with control (FUCRW) or MYC. To explore the effect of RB1 and TP53, we generated LTenza 16D cells with knockdown of RB1 and/or TP53 and compared these lines to control-transduced (shScr) LTenza 16D cells. Enzalutamide-naïve (DMSO-treated) cells were included to validate enzalutamide-induced inhibition of AR signaling in enzalutamide-maintained lines.

2022-05-12 | GSE202897 | GEO

cMyc and Max ChIP-seq analysis in small cell lung carcinoma cells

Project description:cMyc and Max ChIP-seq analysis in a high MYC expressing small cell lung carcinoma cell line (H2171) and a low MYC expressing small cell lung carcinoma cell line (H128).

2012-09-25 | GSE41105 | GEO

Gene expression analysis during reprogramming with sequential infecion of Oct4/Klf4/cMyc/Sox2

2012-07-12 | GSE39260 | GEO